Hedlin Peter, Blondeau Joseph M
Department of Clinical Microbiology, Royal University Hospital and Saskatoon Health Region, Saskatoon, Saskatchewan, Canada.
Eye Contact Lens. 2007 May;33(3):161-4. doi: 10.1097/01.icl.0000246872.73559.43.
Haemophilus influenzae is a known ocular pathogen, particularly in the pediatric population. The purpose of this study was to determine the minimal inhibitory concentration (MIC) and mutant prevention concentration (MPC) values of third-generation (i.e., ciprofloxacin and ofloxacin) and fourth-generation (i.e., gatifloxacin and moxifloxacin) fluoroquinolone antibiotics against clinical ocular isolates of H. influenzae.
Twenty-six clinical isolates of H. influenzae were evaluated. For MIC testing, approximately 10(5) colony-forming units/mL of test organism was added to an H. influenzae test medium containing twofold dilution increments of each fluoroquinolone. Cultures were incubated for 18 to 24 hours at 35 degrees C to 37 degrees C in 5% CO2. The lowest drug concentration that prevented growth was recorded as the MIC. The lowest drug concentration that inhibited 90% of strains tested was recorded as the MIC90. To determine MPC values, more than 10(10) bacteria were inoculated to agar plates containing varying drug concentrations and incubated for 24 to 48 hours at 35 degrees C to 37 degrees C in 5% CO2. To confirm MPC values, bacteria isolated from drug-containing plates were subcultured to drug-free agar, incubated, and then subcultured to a plate with the same drug concentration. The lowest drug concentration that allowed no growth was recorded as the MPC.
All tested fluoroquinolones were highly active against H. influenzae. The MIC90 values were 0.016 microg/mL for gatifloxacin and ciprofloxacin and 0.031 microg/mL for moxifloxacin and ofloxacin. The MPC90 values were 0.125 microg/mL for gatifloxacin and 0.5 microg/mL for moxifloxacin, ofloxacin, and ciprofloxacin.
All evaluated fluoroquinolones were effective against H. influenzae. The MIC90 and MPC90 values for gatifloxacin were consistently lower than those for moxifloxacin.
流感嗜血杆菌是一种已知的眼部病原体，尤其在儿童群体中。本研究的目的是确定第三代（即环丙沙星和氧氟沙星）和第四代（即加替沙星和莫西沙星）氟喹诺酮类抗生素对流感嗜血杆菌临床眼部分离株的最低抑菌浓度（MIC）和突变预防浓度（MPC）值。
对26株流感嗜血杆菌临床分离株进行了评估。对于MIC检测，将约10⁵菌落形成单位/毫升的受试微生物添加到含有每种氟喹诺酮两倍稀释增量的流感嗜血杆菌测试培养基中。培养物在35℃至37℃、5%二氧化碳环境下孵育18至24小时。阻止生长的最低药物浓度记录为MIC。抑制90%受试菌株的最低药物浓度记录为MIC90。为确定MPC值，将超过10¹⁰个细菌接种到含有不同药物浓度的琼脂平板上，并在35℃至37℃、5%二氧化碳环境下孵育24至48小时。为确认MPC值，从含药平板分离的细菌转接至不含药物的琼脂上，孵育后再转接至具有相同药物浓度的平板上。不允许生长的最低药物浓度记录为MPC。
所有受试氟喹诺酮类药物对流感嗜血杆菌均具有高度活性。加替沙星和环丙沙星的MIC90值为0.016微克/毫升，莫西沙星和氧氟沙星的MIC90值为0.031微克/毫升。加替沙星的MPC90值为0.125微克/毫升，莫西沙星、氧氟沙星和环丙沙星的MPC90值为0.5微克/毫升。
所有评估的氟喹诺酮类药物对流感嗜血杆菌均有效。加替沙星的MIC90和MPC90值始终低于莫西沙星。
Zotero 插件